Document:

Exhibit 10.27

 

FORFEITURE AGREEMENT

 

This FORFEITURE AGREEMENT
(this “Agreement”), dated as of December 21, 2021, is made by and among HC Sponsor LLC, a Cayman Islands limited
liability company (the “Sponsor”), a holder of Parent Class B Ordinary Shares and Parent Class A Ordinary
Shares, HealthCor Catalio Acquisition Corp. (“HealthCor”), Liminal Sciences, Inc., a Delaware corporation (“Liminal”),
and Hyperfine, Inc., a Delaware corporation (the “Hyperfine”) (Hyperfine and Liminal are each, a “Company”
and, are collectively, the “Companies”). The Sponsor, HealthCor and the Companies shall be referred to herein from
time to time collectively as the “Parties”. Capitalized terms used but not otherwise defined herein shall have the
meanings ascribed to such terms in the Business Combination Agreement (as defined below).

 

WHEREAS, HealthCor, the Companies
and certain other Persons party thereto entered into that certain Business Combination Agreement, dated as July 7, 2021 (as it may
be amended, restated or otherwise modified from time to time in accordance with its terms, the “Business Combination Agreement”);
and

 

WHEREAS, the Parties have
agreed to proceed with the transactions contemplated by the Business Combination Agreement (subject to its terms and the terms of the
Ancillary Documents), on the basis of the Sponsor entering into this Agreement.

 

NOW, THEREFORE, in consideration
of the premises and the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows:

 

1.            Forfeiture.
Effective as of immediately prior to, and subject to the consummation of, the Closing, Sponsor irrevocably agrees that 150,000 shares
of New Parent Class B Common Stock owned by the Sponsor shall be automatically and irrevocably forfeited by the Sponsor to HealthCor
as a capital contribution and for no consideration other than the consideration set forth in the recitals above, and automatically cancelled
(the “Forfeiture”).

 

2.            Termination.
This Agreement shall automatically terminate, without any notice or other action by any Party, and be void upon the earlier of (a) immediately
after the Forfeiture; and (b) the termination of the Business Combination Agreement in accordance with its terms. Upon termination
of this Agreement as provided in the immediately preceding sentence, none of the Parties shall have any further obligations or Liabilities
under, or with respect to, this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, the termination
of this Agreement pursuant to Section 5(b) shall not affect any Liability on the part of any Party for a Willful Breach
of any covenant or agreement set forth in this Agreement prior to such termination. For purposes of this Section 5, “Willful
Breach” means a material breach that is a consequence of an act undertaken or a failure to act by the breaching Party with
the knowledge that the taking of such act or such failure to act would, or would reasonably be expected to, constitute or result in a
breach of this Agreement.

 

3.            Entire
Agreement. This Agreement, the Business Combination Agreement and documents referred to herein and therein constitute the entire
agreement of the Parties with respect to the subject matter of this Agreement, and supersede all prior agreements and undertakings, both
written and oral, among the Parties with respect to the subject matter of this Agreement, except as otherwise expressly provided in this
Agreement.

 

    

     

    

 

4.            Amendments
and Waivers; Assignment. Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in
writing and signed by all of the Parties hereto. Notwithstanding the foregoing, no failure or delay by any Party in exercising any right
hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise of
any other right hereunder. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assignable by Sponsor
without the prior written consent of the Companies (to be withheld or given in their sole discretion).

 

5.            No
Third Party Beneficiaries. This Agreement shall be for the sole benefit of the Parties and their respective successors and permitted
assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective successors and assigns,
any legal or equitable right, benefit or remedy of any nature whatsoever by reason of this Agreement. Nothing in this Agreement, expressed
or implied, is intended to or shall constitute the Parties, partners or participants in a joint venture.

 

6.            Incorporation
by Reference. Sections 8.5 (Governing Law), 8.7 (Construction; Interpretation), 8.10 (Severability), 8.11 (Counterparts; Electronic
Signatures), 8.15 (Waiver of Jury Trial), 8.16 (Submission to Jurisdiction) and 8.17 (Remedies) of the Business Combination Agreement
are incorporated herein and shall apply to this Agreement mutatis mutandis.

 

    2

     

    

 

IN WITNESS WHEREOF,
each of the Parties has caused this Agreement to be duly executed on its behalf as of the day and year first above written.

 

	 	HEALTHCOR CATALIO ACQUISITION
    CORP.
	 	 
	 	 
	 	By:	/s/
    Christine Clarke 
	 	 	Name: Christine Clarke
	 	 	Title: Chief Financial Officer

 

[Signature Page to Forfeiture Agreement]

 

    

     

    

 

IN WITNESS WHEREOF,
each of the Parties has caused this Agreement to be duly executed on its behalf as of the day and year first above written.

 

	 	SPONSOR:
	 	 
	 	 
	 	HC SPONSOR LLC
	 	 
	 	 
	 	By:	/s/
    Christine Clarke
	 	 	Name: Christine Clarke
	 	 	Title: Chief Financial Officer

 

[Signature Page to Forfeiture Agreement]

 

    

     

    

 

IN WITNESS WHEREOF,
each of the Parties has caused this Agreement to be duly executed on its behalf as of the day and year first above written.

 

	 	COMPANIES:
	 	 
	 	 
	 	HYPERFINE, INC.
	 	 
	 	 
	 	By:	/s/
    Jonathan M. Rothberg
	 	 	Name: Jonathan M. Rothberg
	 	 	Title: Executive Vice Chairman
	 	 
	 	 
	 	LIMINAL SCIENCES, INC.
	 	 
	 	 
	 	By:	/s/ Jonathan M.
    Rothberg
	 	 	Name: Jonathan M. Rothberg
	 	 	Title: Executive Chairman

 

[Signature Page to Forfeiture Agreement]Exhibit 10.1

 

SECURITIES PURCHASE AGREEMENT

 

THIS SECURITIES PURCHASE
AGREEMENT (this “Agreement”), dated as of __, 2021, by and between Brain Scientific, Inc., a Nevada corporation
with its headquarters located at 125 Wilbur Place, Suite 170, Bohemia, NY 11716 (the “Company”), and the investors
from time to time signatory hereto (the “Purchasers”).

 

WHEREAS, the Company
deems it in the best interests of the Company and its stockholders to conduct a private placement offering of up to $______ aggregate
principal amount of its convertible notes (the “Offering”);

 

WHEREAS, the initial
$[_______] of the proceeds of the Offering will be deposited into the escrow account (the “Escrow Account”) established
for that purpose pursuant to the escrow agreement, dated as of the date hereof (the “Escrow Agreement”) among the Company
and the Lucosky Brookman LLP;

 

WHEREAS, on such date
as the amount deposited in the Escrow Account shall equal $5,000,000 or more (the “Initial Funds Release Date”) such
funds will be released to the Company pursuant to the terms of the Escrow Agreement for use by the Company in relation to a proposed merger;

 

WHEREAS, additional
Purchasers may become party to this Agreement from time to time following the date hereof by executing and delivering to the Company their
signed counterpart of a signature page hereto at a minimum investment per Purchaser to be $50,000 which may be waived by the Company in
its sole discretion;

 

WHEREAS, the Company
and the Purchasers are and will be executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the Securities Act of 1933, as amended (the “Securities Act”); and

 

WHEREAS, the parties
hereto desire that, upon the terms and subject to the conditions contained herein, the Company shall issue and sell to Purchasers, and
Purchasers shall purchase in one or more closings, (i) 10% Convertible Promissory Notes substantially in the form of Exhibit A
hereto (each, a “Note” and collectively, the “Notes”), and (ii) the right to receive common stock
purchase warrants in accordance with Section 1(c) hereof, in the form of Exhibit B to purchase shares of common stock, par value
$0.001 per share, of the Company (the “Common Stock”), subject to the terms and conditions therein contained (each,
a “Warrant”, collectively the “Warrants” and together with the Notes, and the Common Stock issuable
upon conversion of the Notes, the “Securities”); and

 

WHEREAS, unless terminated
sooner by the Company, the Offering and sales of the Notes shall terminate on December __, 2021 but may be extended by an additional 90
days in the Company’s sole discretion.

.

 

NOW, THEREFORE, in
consideration of the mutual covenants and other agreements contained in this Agreement, the Company and Purchasers hereby agree as follows:

 

		1.	Closings.

 

		a.	Closing. Subject to the terms and conditions set forth in this Agreement, the Company shall issue
and sell to each Purchaser, and each Purchaser shall, severally and not jointly, purchase from the Company on the applicable Closing Date,
a Note in the principal amount set forth on such Purchaser’s signature page. Each such sale of Notes shall be a deemed a “Closing”
The date of each Closing is hereinafter referred to as a “Closing Date” and shall be determined by the Company and
the applicable Purchaser. The aggregate maximum principal of Notes to be sold to the Purchasers pursuant to this Agreement shall not exceed
$______.

 

     

     

    

 

		b.	Closing Deliveries. At each Closing, the Company shall deliver to the Purchaser or Purchasers participating
in such Closing, against delivery by such Purchasers of their purchase price as set forth on their signature page hereto (the “Purchase
Price”), the Note then being purchased by such Purchaser or Purchasers, and a copy of this Agreement duly signed by an authorized
officer of the Company. At each Closing, each Purchaser participating in such Closing, shall deliver or cause to be delivered to the Company
a copy of this Agreement duly signed by such Purchaser, a completed Investor Questionnaire in the form attached hereto as Exhibit C, and
the Purchase Price set forth in such Purchaser’s counterpart signature page annexed hereto by paying United States dollars in immediately
available funds, by wire transfer if such Closing is prior to the Initial Funds Release Date, to the Escrow Account (as defined in the
Escrow Agreement), and if such Closing is subsequent to the Initial Funds Release Date, in accordance with such wire instructions as shall
be communicated in writing by the Company to such Purchaser.

 

		c.	Warrants. Each holder of a Note purchased hereunder, provided that the Note is still then outstanding,
shall be issued on the earlier (i) the date, if any, upon which the Company’s Common Stock is listed for trading on the NASDAQ stock
exchange (the “Uplist”), and (ii) April 1, 2023, a Warrant to purchase an amount of shares of Common Stock, equal to
such holder’s Warrant Share Amount. For purposes of this Agreement, a holder’s “Warrant Share Amount” shall
mean (i) if such Warrant is issued in connection with the Uplist, one half of the initial principal balance of such holder’s Note
at issuance divided by the lesser of (A) $0.90, and (B) and the greater of (x) $0.20 and (y) one hundred twenty percent (120%) of closing
price for the Common Stock on the Trading Day prior to the date of the Uplist, and (ii) if such Warrant is issued otherwise than in connection
with the Uplist, the initial principal balance of such holder’s Note, divided by the lesser of (A) $0.90, and (B) and the greater
of (x) $0.20 and (y) one hundred twenty percent (120%) of the average VWAP for the Common Stock over the five (5) consecutive Trading
Days immediately preceding April 1, 2023. Further, for purposes of this Agreement (x) “Trading Day” shall mean any
day that shares of Common Stock are traded on the Trading Market, (y) “Trading Market” shall mean, the principal securities
exchange or trading market where the Common Stock is listed or traded, including but not limited to any tier of the OTC Markets, any tier
of the NASDAQ Stock Market (including NASDAQ Capital Market), the New York Stock Exchange, or the NYSE American, or any successor to such
markets, and (z) “VWAP” shall mean means, for any Trading Day, the price determined by the first of the following clauses
that applies: (i) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common
Stock for such Trading Day (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as
reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (ii) if OTCQB
or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on OTCQB or OTCQX as applicable, (iii) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for
the Common Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or
agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (iv)
in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected by mutual agreement
of the Company and the holders owning no less than 50.1% of the then Notes outstanding. Notwithstanding the foregoing, if a holder of
a Note elects to receive the amounts owing under such Note in the form of cash upon an Uplist rather than have such amounts converted
in shares of Common Stock as provided in such Note, then the holder of such Note shall not be entitled to receive a warrant in accordance
with this Section 1(c).

 

    2

     

    

 

2. Purchasers
Representations and Warranties. Each Purchaser, for itself and for no other Purchaser, as of each Closing Date on which such Purchaser
is purchasing Notes and upon the date upon which such Purchaser is being issued Warrants in accordance with Section 1(c) hereof, hereby
acknowledges, represents and warrants as follows (with the understanding that the Company will rely on such representations and warranties
in determining, among other matters, the suitability of this investment for the Purchasers in order to comply with federal and state securities
laws):

 

(a) The Purchaser
has read this Agreement. The Purchaser acknowledges that this Agreement is not intended to set forth all of the information which
might be deemed pertinent by an investor who is considering an investment in the Securities. It is the responsibility of the Purchaser
(i) to determine what additional information he desires to obtain in evaluating this investment, and (ii) to obtain such information from
the Company.

 

(b) Standing
of Purchaser. If Purchaser is an entity, such Purchaser is duly organized, validly existing and in good standing under the laws of
the jurisdiction of its formation. If Purchaser is a natural person, such Purchasers is not a minor and has the legal capacity to enter
into this Agreement;

 

(c) Authorization
and Power. Purchaser has the requisite power and authority to enter into and perform this Agreement and to purchase the Notes and
accept the Warrants. The execution, delivery and performance of this Agreement by Purchaser and, if Purchaser is an entity, the consummation
by Purchaser of the transactions contemplated hereby have been duly authorized by all necessary company action, and no further consent
or authorization of Purchaser, its board of directors or similar governing body, or stockholders is required, as applicable. This Agreement
has been duly authorized, executed and delivered by Purchaser and constitutes, or shall constitute when executed and delivered, a valid
and binding obligation of Purchaser, enforceable against Purchaser in accordance with the terms thereof;

 

(d) No Conflicts.
If Purchaser is an entity, the execution, delivery and performance of this Agreement and the consummation by Purchaser of the transactions
contemplated hereby do not and will not result in a violation of Purchaser’s charter documents, bylaws or other organizational documents,
as applicable;

 

(e) Purchaser
Information. Purchaser is an “accredited investor,” as such term is defined in Rule 501(a) of Regulation D promulgated
by the SEC under the Securities Act and affirmed by Purchaser in the completed Investor Questionnaire attached hereto as Exhibit C,
is experienced in investments and business matters, has made investments of a speculative nature and has purchased securities of United
States publicly-owned, reporting companies whose common stock is quoted on the OTC Pink Market, has an extremely limited trading market,
if any, substantial debt and limited revenues, cash or other assets, in private placements in the past and, has such knowledge and experience
in financial, tax and other business matters as to enable Purchaser to utilize the information made available by the Company and/or that
is publicly available including on the SEC’s website to evaluate the merits and risks of and to make an informed investment decision
with respect to the proposed purchase, which represents a speculative investment. Purchaser is able to bear the risk of such investment
for an indefinite period and to afford a complete loss thereof. The information in any documents delivered by the Purchaser in connection
with this Agreement, including, but not limited to the Purchaser Questionnaire, is true, correct and complete in all respects as of the
date hereof. The Purchaser agrees promptly to notify the Company in writing of any change in such information after the date hereof. Purchasers
is not required to be registered as a broker-dealer under Section 15 of the Securities Exchange Act of 1934 (the “Exchange Act”),
as amended;

 

(f) Purchase
of Notes and Warrants. Purchaser will purchase the Securities for its own account for investment and not with a view toward, or for
resale in connection with, the public sale or any distribution thereof in violation of the Securities Act or any applicable state securities
law, and has no direct or indirect arrangement or understandings with any other person or entity to distribute or regarding the distribution
of such Securities;

 

(g) Compliance
with Securities Act. Purchaser understands and agrees that the Securities are “restricted securities” and have not been
registered under the Securities Act or any applicable state securities laws by reason of their issuance in a transaction that does not
require registration under the Securities Act, and that such Securities must be held indefinitely unless a subsequent disposition is registered
under the Securities Act or any applicable state securities laws or is exempt from such registration;

 

    3

     

    

 

(h) Restricted
Securities. The Purchaser understands that the Offering of the Securities has not been registered under the Securities Act, in reliance
on an exemption for private offerings provided pursuant to Section 4(2) of the Act and that, as a result, the Securities will be “restricted
securities” as that term is defined in Rule 144 under the Act and, accordingly, under Rule 144 as currently in effect, that the
Securities must be held for at least one (1) year after the investment has been made (or indefinitely if the Purchasers is deemed an “affiliate”
within the meaning of such rule) unless the Securities is subsequently registered under the Act and qualified under any other applicable
securities law or exemptions from such registration and qualification are available. The Purchasers further understands that the Offering
of the Securities has not been qualified or registered under any foreign or state securities laws in reliance upon the representations
made and information furnished by the Subscriber herein and any other documents delivered by the Purchasers in connection with this Agreement;
that the Offering has not been reviewed by the SEC or by any foreign or state securities authorities; that the Purchaser’s rights
to transfer the Securities will be restricted, which includes restrictions against transfers unless the transfer is not in violation of
the Act and applicable state securities laws (including investor suitability standards); and that the Company may in its sole discretion
require the Purchasers to provide at Purchaser’s own expense an opinion of its counsel to the effect that any proposed transfer
is not in violation of the Act or any state securities laws.

 

(i) Legends.
The Purchaser understands and agrees that the Company will cause any necessary legends in addition to representations to be placed upon
any instruments(s) evidencing ownership of the Securities, together with any other legend that may be required by federal or state securities
laws or deemed necessary or desirable by the Company.

 

(j)  No Integrated
Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly
made any offers or sales in any security or solicited any offers to buy any security under circumstances that would require registration
under the Securities Act of the issuance of the Securities to the Purchaser. The issuance of the Securities to the Buyer will not be integrated
with any other issuance of the Company’s securities (past, current or future) including, without limitation, for purposes of any
shareholder approval provisions applicable to the Company or its securities.

 

(k) No Governmental
Endorsement. Purchaser understands that no United States federal or state agency or any other governmental or state agency has passed
on or made recommendations or endorsement of the Securities or the suitability of the investment in the Securities, nor have such authorities
passed upon or endorsed the merits of the offering of the Securities;

 

(l) Receipt
of Information. Purchaser believes it has received all the information it considers necessary or appropriate for deciding whether
to purchase the Securities. Purchaser further represents that through its representatives it has had an opportunity to ask questions and
receive answers from the Company regarding the terms and conditions of the offering of the Securities and the business, properties and
financial condition of the Company and to obtain additional information (to the extent the Company possessed such information or could
acquire it without unreasonable effort or expense) necessary to verify the accuracy of any information furnished to it or to which it
had access; and

 

(m) No Market
Manipulation. Purchasers and Purchaser’s affiliates have not taken, and will not take, directly or indirectly, any action designed
to, or that might reasonably be expected to, cause or result in stabilization or manipulation of the price of the Common Stock, to facilitate
the sale or resale of the Securities or affect the price at which the Securities may be issued or resold.

 

3. Company Representations
and Warranties. The Company represents and warrants to, and agrees with, each Purchaser as of the date such Purchaser has first purchased
Securities hereunder that:

 

(a) Due Incorporation.
The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the jurisdiction of its incorporation;

 

(b) Authority;
Enforceability. This Agreement has been duly authorized, executed and delivered by the Company and is the valid and binding agreement
of the Company, enforceable in accordance with their terms, except as may be limited by bankruptcy, insolvency, moratorium or other similar
laws affecting the enforcement of creditors’ rights generally, or principles of equity. The Company has full corporate power and
authority necessary to enter into and deliver this Agreement and to perform its obligations thereunder;

 

    4

     

    

 

(c) Capitalization
and Additional Issuances. Promptly following the date hereof, the Company will inform each Purchaser of (i) the amount of shares of
authorized shares of Common Stock and shares of preferred stock of the Company and (ii) the amount of shares of the Common Stock issued
and outstanding and shares of the Common Stock which may be issued hereafter in respect of stock options, warrants, convertible securities
preferred stock or other Company Securities (as defined below) issued or outstanding, as of the date of such notification. All of the
outstanding shares of the Common Stock are, and the Common Stock to be issued pursuant to the Note and Warrant will be, duly authorized
and validly issued, fully paid and non-assessable and are not (and will not be) subject to preemptive or similar rights affecting the
Common Stock. As of the date hereof, except as described on Schedule 3(c) hereto, there are no (i) contracts to which the Company is a
party obligating the Company to accelerate the vesting of any company equity award as a result of the transactions contemplated by this
Agreement (whether alone or upon the occurrence of any additional or subsequent events), (ii) outstanding securities of the Company convertible
into or exchangeable for shares of the Common Stock or other Securities, (iii) outstanding options, warrants or other agreements or commitments
to acquire from the Company, or obligations of the Company to issue, shares of capital stock of (or securities convertible into or exchangeable
for shares of capital stock of) the Company, or (iv) restricted shares, restricted stock units, stock appreciation rights, performance
shares, profit participation rights, contingent value rights, “phantom” stock or similar securities or rights that are derivative
of, or provide economic benefits based, directly or indirectly, on the value or price of, any shares of capital stock of the Company,
in each case that have been issued by the Company (the items in clauses (i), (ii) (iii) and (iv), together with the capital stock of the
Company, being referred to collectively as “Company Securities”). There are no outstanding contracts requiring the
Company to repurchase, redeem or otherwise acquire any Company Securities and the Company is not a party to any voting agreement with
respect to any Company Securities;

 

(d) SEC
Filings; Financial Statements; Absence of Undisclosed Liabilities.

 

(i) SEC Filings.
The Company has filed with the SEC all reports, schedules, forms, statements and other documents (including exhibits and all other information
incorporated by reference) required to be filed or furnished by it with the SEC since June 1, 2021 (the “Company SEC Documents”)
and such Company SEC Documents when filed were true, correct and complete in all material respects. As of their respective filing dates
(or, if amended or superseded by a subsequent filing, as of the date of the last such amendment or superseding filing prior to the date
hereof), each of the Company SEC Documents complied in all material respects with the applicable requirements of the Sarbanes-Oxley Act
of 2002 (including the rules and regulations promulgated thereunder) and the Exchange Act, and the rules and regulations of the SEC thereunder
applicable to such Company SEC Documents and did not, at the time it was filed (or, if amended, at the time (and taking into account the
content) of such amendment), contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The
Company has made available to Purchasers correct and complete copies of all correspondence between the SEC, on the one hand, and the Company
and any of its subsidiaries, on the other hand, occurring since [Date], and prior to the date hereof. As of the date hereof, none of the
Company SEC Documents is the subject of ongoing SEC review, outstanding SEC comment or outstanding SEC investigation;

 

 

(ii) Financial
Statements. On October 1, 2021 the Company closed a merger with Piezo Motion Corporation. The applicable Financial Statements and
Pro Forma Financial Statements for Piezo Motion Corporation (the “Piezo Financials”) will be filed within 71 days of October
1, 2021. With the exception of the Piezo Financials, the consolidated financial statements (including, in each case, any related notes
thereto) contained in the Company SEC Documents: (i) complied as to form in all material respects with the published rules and regulations
of the SEC with respect thereto as of their respective dates; (ii) was prepared in accordance with United States generally accepted accounting
principles (“GAAP”) applied on a consistent basis throughout the periods involved (except as may be indicated in the
notes thereto and, in the case of unaudited interim financial statements, as may be permitted by the SEC for Quarterly Reports on Form
10-Q); and (iii) fairly presented in all material respects the consolidated financial position of the Company at the respective dates
thereof and the consolidated results of the Company’s operations and cash flows for the periods indicated therein, subject, in the
case of unaudited interim financial statements, to normal and year-end audit adjustments as permitted by GAAP and the applicable rules
and regulations of the SEC. As of the date hereof, Sadler, Gibb & Associates, LLC has not resigned or been dismissed as independent
public accountants of the Company as a result of or in connection with any disagreements with the Company on a matter of accounting principles
or practices, financial statement disclosure or auditing scope or procedure;

 

    5

     

    

 

(iii) No Undisclosed
Liabilities. Except as set forth on schedule 3(d) which contains liabilities of Piezo Motion Corporation as June 30, 2021, neither
the Company nor any of its subsidiaries has any liability, indebtedness or obligation of any kind (whether accrued, absolute, contingent,
matured, unmatured or otherwise, and whether or not required to be recorded or reflected on a balance sheet under GAAP) (“Liability”)
except for Liabilities that (a) are reflected or recorded on the Company’s most recent balance sheet included in the Company SEC
Documents (including in the notes thereto but only to the extent it is reasonably apparent that the disclosure in such notes is of a Liability
required to be reflected on a balance sheet prepared in accordance with GAAP) contained in the Company SEC Documents or (b) are current
Liabilities (within the meaning of GAAP) which were incurred since the date of such balance sheet in the ordinary course of business consistent
with past practice;

 

(e)  Related
Party Transactions. Except as set forth on schedule 3(e), all contracts, transactions, arrangements and understandings with any executive
officer or director of the Company or any of its subsidiaries, any other person that directly or indirectly controls, is controlled by
or is under common control with ( “Affiliate”), the Company, or any person owning 5% or more of the shares of the Common
Stock (or any of such person’s immediate family members or Affiliates or associates), which is required to be disclosed under Item
404 of Regulation S-K promulgated under the Securities Act, have been fully and properly disclosed in the appropriate Company SEC Documents.
To the Company’s knowledge there are no such contracts, transactions, arrangements or understandings which have not been so disclosed;

 

(f) Consents.
No consent, approval, authorization or order of any court, governmental agency or body having jurisdiction over the Company or of any
other person is required for the execution by the Company of this Agreement and compliance and performance by the Company of its obligations
hereunder, including, without limitation, the issuance of Shares and Warrant and sale of the Shares;

 

(g) No Violation
or Conflict. Neither the issuance of the Warrant nor the issuance and sale of the Shares nor the performance of the Company’s
obligations under this Agreement will:

 

(i) violate, conflict
with, result in a breach of, or constitute a default (or an event which with the giving of notice or the lapse of time or both would be
reasonably likely to constitute a default) under (a) the charter or bylaws of the Company or (b) any decree, judgment, order or determination
applicable to the Company of any court, governmental agency or body having jurisdiction over the Company or over the properties or assets
of the Company or (c) any contract, agreement, instrument or undertaking to which the Company or any subsidiary is a party; or

 

(ii) result in the
creation or imposition of any lien, charge or encumbrance upon the Securities except in favor of Purchasers as described herein;

 

(h) Litigation.
There is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or investigation before or by any court,
governmental agency or body having jurisdiction over the Company including, without limitation, any such that would affect the execution
by the Company or the complete and timely performance by the Company of its obligations under this Agreement. The Company has not, since
[Date], been a party to any material litigation, arbitration or other proceeding, other than what has been previously disclosed by the
Company in the Company SEC Documents;

 

(i) No General
Solicitation. Neither the Company, nor any of its affiliates, nor any person or entity acting on its or their behalf, has engaged
in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection
with the offer or sale of the Shares;

 

(j) Investment
Company. The Company is not an “investment company” within the meaning of the Investment Company Act of 1940, as amended;

 

(k) Listing
and Maintenance Requirements. The Company is, and has no reason to believe that it will not in the foreseeable future continue to
be, in compliance with the listing and maintenance requirements for continued listing or quotation of the Company Common Stock on the
trading market on which the Company Common Stock is currently listed or quoted. The issuance and sale of the Shares under this Agreement
does not contravene the rules and regulations of the trading market on which the Company Common Stock is currently listed or quoted, and
no approval of the stockholders of the Company is required for the Company to issue and deliver to the Purchasers the Shares contemplated
by this Agreement; and

 

    6

     

    

 

(l) Full Disclosure.
No representation or warranty or other statement made by the Company in this Agreement in connection with the contemplated transactions
contains any untrue statement of material fact or omits to state a material fact necessary to make the representations and warranties
set forth herein, in light of the circumstances in which they were made, not misleading.

 

(m) No Defaults. Except
as described in the SEC Documents, no material default exists in the due performance and observance of any term, covenant or condition
of any permit, license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument
evidencing an obligation for borrowed money, or any other agreement or instrument to which the Company is a party or by which the Company
may be bound or to which any of the properties or assets of the Company is subject the effect of which would have a Material Adverse Effect.
Except as described SEC filings, the Company is not in violation of any material term or provision of its Certificate of Incorporation,
By-Laws or in material violation of any franchise, license, permit, applicable law, rule, regulation, judgment or decree of any governmental
agency or court, domestic or foreign, having jurisdiction over the Company or any of its properties or business.

 

(n) No Preemptive Rights;
Options. Except as set forth on schedule 3(n) or the SEC Documents, there are no preemptive or other rights to subscribe for or purchase,
or any restriction upon the voting or transfer of, any shares of Common Stock, or other securities of the Company.

 

(o) Registration Rights
of Third Parties. Except as set forth schedule 3(o), no holders of any securities of the Company or of any options or warrants of
the Company exercisable for or convertible or exchangeable into securities of the Company have the right to require the Company to register
any such securities of the Company under the Act or to include any such securities in a registration statement to be filed by the Company.

 

4. Adjustments for Stock
Splits. In the event and to the extent that the Company consummates a reverse stock split or forward stock split prior to the closing
of transactions contemplated by this Agreement, the number of issuable shares of Common Stock purchased under this agreement, including
the shares underlying the Note and the shares of Common Stock issuable pursuant to the Warrant shall be proportionately and equitably
adjusted.

 

5. Registration Statement.
Within 90 days of the date hereof, the Company shall prepare and file with the Commission a registration statement under the Securities
Act including the shares of Common Stock issuable pursuant to the terms of the Notes. Within 45 days of the date of the issuance of Warrants
in accordance with Section 1(c) hereof, the Company shall prepare and file with the Commission a registration statement under the Securities
Act including the Warrants and the shares of Common Stock issuable upon exercise of the Warrants.

 

6. Broker’s
Commission/Finder’s Fee. The Company reserves the right to retain registered broker/dealers and others to assist the Company
in selling the Notes and Warrants in the Offering and to pay any such persons cash commissions of up to 10% in connection therewith.

 

7. Covenants Regarding
Indemnification. Each party hereto agrees to indemnify, hold harmless, reimburse and defend the other party and the other party’s
officers, directors, agents, counsel, affiliates, members, managers, control persons, and principal shareholders, as applicable, against
any claim, cost, expense, liability, obligation, loss or damage (including reasonable legal fees) of any nature, incurred by or imposed
upon the indemnified party or any such person which results, arises out of or is based upon (i) any breach of any representation or warranty
by the indemnifying party in this Agreement or (ii) any breach or default in performance by the indemnifying party of any covenant or
undertaking to be performed by the indemnifying party.

 

8. Intellectual
Property Rights. The Company and its subsidiaries own or possess adequate rights or licenses to use all trademarks, trade names, service
marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations,
trade secrets and rights necessary to conduct their respective businesses as now conducted. The Company and its subsidiaries do not have
any knowledge of any infringement by the Company or its subsidiaries of trademark, trade name rights, patents, patent rights, copyrights,
inventions, licenses, service names, service marks, service mark registrations, trade secret or other similar rights of others, or of
any such development of similar or identical trade secrets or technical information by others and, except as set forth on Schedule 3,
there is no claim, action or proceeding being made or brought against, or to the Company’s knowledge, being threatened against,
the Company or its subsidiaries regarding trademarks, trade name rights, patents, patent rights, inventions, copyrights, licenses, service
names, service marks, service mark registrations, trade secrets or other.

 

    7

     

    

 

9. Foreign Corrupt
Practices Act. To the Company’s knowledge, neither the Company, nor any director, officer, agent, employee or other person acting
on behalf of the Company or any subsidiary has, in the course of acting for, or on behalf of, the Company, directly or indirectly used
any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; directly
or indirectly made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds;
violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any similar treaties of
the United States; or directly or indirectly made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment to
any foreign or domestic government or party official or employee.

 

10. Miscellaneous.

 

(a) Notices.
Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given on the earliest of: (i) the
date delivered, if delivered by personal delivery as against written receipt therefor or by email or by facsimile (with successful transmission
confirmation as to both of the foregoing), (ii) the earlier of the date delivered or the third Business Day  after deposit, postage
prepaid, in the United States Postal Service by certified mail, return receipt requested, or (iii) the earlier of the date delivered
or the third Business Day after sent by express courier, with delivery costs and fees prepaid, in each case, addressed to each of the
parties hereto at the following addresses (or at such other addresses as such party may designate by five (5) calendar days’
advance written notice similarly given to the other party hereto):

 

If to the Company:

Brain Scientific,
Inc.

6700 Professional Parkway

Lakewood Ranch, Florida

Attention: Bonnie-Jeanne
Gerety

Email: Bjgerety@piezomotion.com

 

If to each Purchaser:

As set forth on
its signature page hereto.

 

(b) Entire Agreement;
Assignment. This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and
may be amended only by a writing executed by both parties hereto. Neither the Company nor Purchasers has relied on any representations
not contained or referred to in this Agreement and the documents delivered herewith.

 

(c) Counterparts/Execution.
This Agreement may be executed in any number of counterparts and by the different signatories hereto on separate counterparts, each of
which, when so executed, shall be deemed an original, but all such counterparts shall constitute but one and the same instrument. This
Agreement may be executed by facsimile transmission, PDF, electronic signature or other similar electronic means with the same force and
effect as if such signature page were an original thereof.

 

(d) Governing
Law; Jurisdiction Etc. This Agreement and the terms and conditions set forth herein, shall be governed by and construed solely and
exclusively in accordance with the internal laws of the State of New York without regard to the conflicts of laws principles thereof.
The parties hereto hereby expressly and irrevocably agree that any suit or proceeding arising directly and/or indirectly pursuant to or
under this Agreement shall be brought solely in a federal or state court located in the City, County and State of New York. By its execution
hereof, the parties hereto covenant and irrevocably submit to the in personam jurisdiction of the federal and state courts located in
the City, County and State of New York and agree that any process in any such action may be served upon any of them personally, or by
certified mail or registered mail upon them or their agent, return receipt requested, with the same full force and effect as if personally
served upon them in New York, New York. The parties hereto expressly and irrevocably waive any claim that any such jurisdiction is not
a convenient forum for any such suit or proceeding and any defense or lack of in personam jurisdiction with respect thereto. In the event
of any such action or proceeding, the party prevailing therein shall be entitled to payment from the other parties hereto of all of its
reasonable counsel fees and disbursements.

 

    8

     

    

 

(e) Severability.
In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable
under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith
and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable
under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereto hereby irrevocably
waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Agreement
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law.

 

(f) Captions.
The captions of the various sections and paragraphs of this Agreement have been inserted only for the purposes of convenience; such captions
are not a part of this Agreement and shall not be deemed in any manner to modify, explain, enlarge or restrict any of the provisions of
this Agreement.

 

(g) Confidentiality.
Each Purchaser covenants and agrees that it will keep confidential and will not disclose or divulge any confidential or proprietary information
that such Purchaser may obtain from the Company pursuant to financial statements, reports, and other materials submitted by the Company
to such Purchaser in connection with this Offering or as a result of discussions with or inquiry made to the Company, unless such information
is known, or until such information becomes known, to the public through no action by the Purchaser; provided, however, that a Purchaser
may disclose such information to its attorneys, accountants, consultants, and other professionals to the extent necessary in connection
with his or her investment in the Company so long as any such professional to whom such information is disclosed is made aware of the
Purchaser’s obligations hereunder and such professional agrees to be likewise bound as though such professional were a party hereto.

 

(h) Entire Agreement.
This Agreement (including the Exhibits attached hereto) and other offering documents delivered at the Closings, contain the entire understanding
of the parties in respect of its subject matter and supersedes all prior agreements and understandings between or among the parties with
respect to such subject matter. The Exhibits constitute a part hereof as though set forth in full above.

 

(i) WAIVER OF JURY TRIAL.
EACH HOLDER AND THE COMPANY HEREBY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY
ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT AND/OR THE TRANSACTIONS CONTEMPLATED HEREUNDER.

 

(j) Amendment;
Waiver. This Agreement may not be modified, amended or waived, except by written instrument executed by the Company and a particular
Purchaser but just to that Purchaser, or by the Company and holders owning no less than a majority of the aggregate principal amount of
Notes then outstanding, in which event, such modification, amendment or waiver will apply to all Purchasers including the Purchaser. No
failure to exercise and no delay in exercising, any right, power or privilege under this Agreement shall operate as a waiver, nor shall
any single or partial exercise of any right, power or privilege hereunder preclude the exercise of any other right, power or privilege.
No waiver of any breach of any provision shall be deemed to be a waiver of any proceeding or succeeding breach of the same or any other
provision, nor shall any waiver be implied from any course of dealing between the parties. No extension of time for performance of any
obligations or other acts hereunder or under any other agreement shall be deemed to be an extension of the time for performance of any
other obligations or any other acts. The rights and remedies of the parties under this Agreement are in addition to all other rights and
remedies, at law or equity, that they may have against each other.

 

(k) Senior Debt/Term
of Future Financings. So long as any Note is outstanding, neither the Company nor any of its subsidiaries shall incur indebtedness
senior to the indebtedness represented by the Notes. So long as any Note is outstanding, upon any issuance by the Company or any of its
subsidiaries of any security with any term more favorable to the holder of such security or with a term in favor of the holder of such
security that was not similarly provided to the Purchasers, then the Company shall notify the then holder of any Note of such additional
or more favorable term and such term, at the then holder’s option, shall become a part of the transaction documents with the such
then holder. The types of terms contained in another security that may be more favorable to the holder of such security include, but are
not limited to, terms addressing conversion discounts, prepayment rate, conversion lookback periods, interest rates, original issue discounts,
stock sale price, private placement price per share, and warrant coverage.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    9

     

    

 

SIGNATURE PAGE TO SECURITIES PURCHASE AGREEMENT

 

INFORMATION IN RESPONSE TO THIS SECTION WILL
BE KEPT STRICTLY CONFIDENTIAL

 

	PURCHASE PRICE:	$	 

 

AMOUNT INVESTED TO BE SENT VIA WIRE

 

	Name in Which Note and Warrants Should Be Issued:	 
	 	 
	Principal Amount of Note:	 
	 	 
	 	 

 

	Name of Purchaser:	 
	 	 
	Taxpayer ID Number:	 
	 	 
	        OR	 
	 	 
	Social Security Number:	 
	 	 

 

Address Information:

 

For individual subscribers this address should
be the Purchaser’s primary legal residence. For entities other than an individual Purchaser, please provide address information
for the entities primary place of business. Information regarding a joint subscriber should be included in the column at right.

 

	 	 	 
	Legal Address	 	Legal Address
	 	 	 
	 	 	 
	City, State, and Zip Code	 	City, State, and Zip Code

 

	AGREED AND ACCEPTED	 	AGREED AND ACCEPTED 
	 	 	 	 	 
	This ___ day of _________, 2021	 	This ___ day of _______, 2021
	 	 	 	 	 
	By:	 	 	By:	 
	 	Name: 	 	 	Name: 
	 	Title (if any): 	 	 	Title: 

 

    10

     

    

 

CERTIFICATE OF SIGNATORY

 

(To be completed if the Securities are

being subscribed for by an entity)

 

I______________________ am the ___________________________ of ___________________________
(the “Entity”).

 

I certify that I am empowered and duly authorized
by the Entity to execute and carry out the terms of the Securities Purchase Agreement and to purchase and hold the Notes and Warrants,
and certify further that the Securities Purchase Agreement has been duly and validly executed on behalf of the Entity and constitutes
a legal and binding obligation of the Entity.

 

IN WITNESS WHEREOF, I have set my hand this ____
day of _______________, 2021.

 

	 	 
	(Signature)	 

 

    11

     

    

 

Schedule 3(d)

 

	 	 	As of

 June 30,

 2021	 
	 	 	(Unaudited)	 
	Liabilities	 	 	 
	Current liabilities	 	 	 
	Accounts payable & accrued liabilities	 	$	1,683,452	 
	Accrued interest	 	 	140,123	 
	Note payable	 	 	3,469,982	 
	Lease liability	 	 	68,529	 
	Total current liabilities	 	 	5,362,086	 
	 	 	 	 	 
	Paycheck protection loan	 	 	-	 
	Lease liability, non-current	 	 	128,766	 
	Total Liabilities	 	 	5,490,852	 

 

    12

     

    

 

Schedule (e)

 

None

 

    13

     

    

 

Schedule 3(n)

 

As disclosed in the 8K filed
on October 7, 2021, the Company issued an aggregate of $5,439,476 in principal amount of 10% Notes to accredited investors (the "Note
Offering") on October 1, 2021.  The Note Offering contained the same terms as the ones being offered pursuant to the
offering hereunder.  All such investors have the same registration rights offered hereby. 

 

    14

     

    

 

Schedule 3(o)

 

None

    15

     

    

 

Exhibit A

 

[FORM OF CONVERTIBLE NOTE]

 

     

     

    

 

Exhibit
B

 

[Form
of Common Stock Purchase Warrant]

 

     

     

    

  

Exhibit C

 

[FORM OF INVESTOR QUESTIONNAIRE]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]